Paratek Announces New Board Member

Sep 29, 2004, 01:00 ET from Paratek Pharmaceuticals, Inc.

    BOSTON, Sept. 29 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today
 announced the appointment of Malcolm L. Sherman to the Company's Board of
 Directors.  Paratek is a privately held, pharmaceuticals company engaged in
 the development of new anti-infective therapies against drug-resistant
 pathogens and therapies for the treatment of serious inflammation-related
 diseases for which there are few effective therapies.  The appointment of Mr.
 Sherman raises the number of Board members at Paratek to nine and is effective
     "Malcolm brings substantial financial expertise, and we are pleased that
 he has joined our Board," commented Paratek Pharmaceuticals' Chief Executive
 Officer, Thomas J. Bigger.  "In addition to his successful stewardship of
 leading companies in the retail sector, Malcolm has played a prominent role in
 the life of the medical community, including his activities as the former
 chairman of the board of trustees of Tufts - New England Medical Center and as
 a board member of the Whitehead Institute and Massachusetts Eye and Ear, among
 others.  We believe his expert counsel will greatly aid our transition as we
 accelerate the advancement of our breakthrough products."
     Mr. Sherman is Chairman of Gordon Brothers, Inc., a Boston-based firm
 providing global financial, operating and advisory services to companies at
 times of growth or restructuring.  During his career, Mr. Sherman has headed
 many of the leading firms in his sector, previously holding the positions of
 Chairman and CEO at Channel Home Center, Inc., Regina Electric, Inc. and EKCO
 Group.  He also had a distinguished career at Zayre, attaining the positions
 of Executive Vice President at Zayre Corporation and President at Zayre
     From 1997 to 2003, Mr. Sherman served as Chairman of the Board of Trustees
 of Tufts - New England Medical Center, overseeing the transition of Tufts -
 NEMC from the Lifespan system to its original status as an independent, free
 standing, not-for-profit teaching hospital.  Mr. Sherman remains a governor
 and trustee of Tufts - NEMC.  He is also Vice Chairman of the board of
 trustees at Brandeis University and the past Chairman of the board of trustees
 at the Boston Museum of Science, where he remains on the board.  Mr. Sherman
 is also a board member of Massachusetts Eye and Ear Infirmary, the Molecular
 Cardiology Research Institute, Whitehead Institute and Lifespan Corporation.
     About Paratek Pharmaceuticals
     Paratek Pharmaceuticals, Inc. is engaged in the discovery and
 commercialization of new therapeutics that treat serious and life-threatening
 diseases, with a particular focus on the growing worldwide problem of
 antibiotic resistance.  Paratek's lead programs are advancing novel compounds
 that can circumvent or block bacterial resistance, as well as drugs that can
 prevent infection by interfering with Multiple Adaptational Response (MAR)
 mechanisms in bacteria.  Out of these efforts, Paratek has discovered a new
 class of antibiotics, the aminomethylcyclines (including BAY 73-7388) that
 target the need for new and potent antibacterials to overcome the problem of
 rapidly growing bacterial resistance.  BAY 73-7388 is being developed in a
 collaborative partnership with Bayer HealthCare AG for the treatment of
 serious infections.
     Outside the antibacterial therapeutic area, Paratek has also established
 an internal effort to exploit the Company's novel family of compounds and
 their unique mechanism of action in selected anti-inflammatory and
 neurodegenerative conditions.  Paratek has an active chemical synthesis effort
 within this family of compounds to produce novel and diverse small molecules,
 with the goal of developing non-antibacterial products with improved activity
 in serious diseases based upon a growing body of clinical and basic research
 supporting this approach.
     Paratek is privately held and headquartered in Boston, Massachusetts, USA.
 For more information, visit Paratek's website at

SOURCE Paratek Pharmaceuticals, Inc.